ReviewZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2025
[Frontier advances in chimeric antigen receptor T cells and chimeric antigen receptor regulatory T cells therapies for autoimmune diseases].
Review in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune diseases (AID) are disorders in which the immune system mistakenly attacks the body's own tissues. However, current immunosuppressive therapies seldom achieve durable, drug-free remission, indicating the urgent need for therapeutic strategies that are both more precise and longer-lasting. Chimeric antigen receptor (CAR) -T cells are generated by genetically engineering T cells to specifically recognize and kill cells that express particular antigens, thereby providing a novel therapeutic approach for AID. This review summarizes the immunological mechanisms of CAR-T cells and -regulatory T cells (Treg) in treating AID, and systematically reviews the latest advances in applying these treatments to rheumatic AID, immune-mediated neurological AID, and refractory autoimmune hemolytic anemia, among others. Further, we discuss the safety-related limitations of CAR-T /CAR-Treg treatment for AID, and outline other CAR-based cellular therapies that can be used to treat AID beyond CAR-T and CAR-Treg cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.